pocketful logo light
pocketful logo light
Kopran Ltd logo

Kopran Ltd

NSE: KOPRAN BSE: 524280

206.27

(6.56%)

Mon, 01 Jun 2026, 05:07 am

Kopran Share Price Live Chart

1 Day

(6.56%)

No Result Found

Summary

  • Market Cap

    996.37

  • Net Profit

    38.55

  • P/B

    1.63

  • Sector P/E

    33.76

  • P/E

    21.94

  • EV/EBITDA

    12.58

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    7.64

  • ROCE

    9.60

  • Debt/Equity

    0.24

  • EPS (TTM)

    5.33

  • Dividend Yield

    0

  • Book Value

    109.82

  • Interest Cover

    6.56

Analysis

all

thumbs up icon

Pros

  • Kopran is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kopran is profitable, therefore cash runway is not a concern.
  • Kopran is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (39.4%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 2.4x debt.
thumbs up icon

Cons

  • Unable to evaluate Kopran's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kopran's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Kopran's level of debt (49%) compared to net worth is high (greater than 40%).
  • High level of physical assets or inventory.
  • The average tenure for the Kopran board of directors is less than 3 years, this suggests a new board.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters44.4244.4244.4244.4244.42
FII0.570.360.600.761.12
DII0.000.000.000.000.00
Public55.0055.2254.9854.8254.45
Government00000

Read More

Technical Analysis

RSI

67.25

MACD

11.85

50 DMA

151.37

200 DMA

150.31

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic333.67262.32234.30190.97162.95119.6248.27
Fibonacci262.32235.07218.23190.97163.72146.88119.62
Camarilla225.89219.35212.81190.97199.73193.19186.65

Pivots Level: Classic

R3

+142.70

333.67

R2

+71.35

262.32

R1

+43.32

234.30

190.97
190.97
Pivot Point
LTP: 195.96

S1

-28.03

162.95

S2

-71.35

119.62

S3

-142.70

48.27

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    184.41

  • 20-EMA

    174.24

  • 30-EMA

    167.55

  • 50-EMA

    158.90

  • 100-EMA

    151.48

  • 200-EMA

    155.71

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
19 May 2026board-meetingsAccounts, Quarterly Results, Dividend
30 Apr 2026egm
22 Jan 2026board-meetingsQuarterly Results
12 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
04 Aug 2025dividendFinal Dividend - Rs. - 304 Sept 2025
29 Jul 2025agm
15 May 2025dividend₹3.00 Dividend /Share04 Sept 2025
19 Aug 2024agm
02 Aug 2024dividendAnnual General Meeting/Dividend - Rs 3 Per Share03 Sept 2024
16 May 2024dividend₹3.00 Dividend /Share03 Sept 2024

Read More

Peer Comparison

Kopran Ltd logo

Kopran Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Kopran Ltd About

Kopran is engaged in the business of manufacturing of Formulation (Finished Dosage Form).

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1958

Headquarters

CEO

Susheel G Somani

Employees

Contact

Website icon

Website

http://www.kopran.com

Email icon

Email

sunil@kopran.com

Phone icon

Phone

91-22-43661111

Location icon

Location

Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018

Read More

Kopran Ltd Company History

YearHistory
2005
  • The Company appointed Mr.H.P.Vyas as Company Secretary
  • The Company entered into a Strategic Alliance with Merck Specialities Pvt Ltd
2006
  • The company signed a distribution pact with Mumbai-based Manish Pharma for its complete range of over the counter (OTC) products
2011
  • The company appointed Mr. Abhinav Mathur as a Company Secretary & Compliance Officer
2013
  • Kopran Ltd. launched a new brand SPARKLE in the FMCG category
2018
  • Kopran Research Laboratories Limited, a wholly owned subsidiary of the Company purchased API facility at Panoli, Gujarat

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDbulkBuy265749196.226 May 2026
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDbulkSell682777194.726 May 2026
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDbulkBuy2563633192.8425 May 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkBuy367795188.0125 May 2026
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDbulkBuy26700192.6225 May 2026
YUGA STOCKS AND COMMODITIES PRIVATE LIMITEDbulkSell409820195.825 May 2026
SETU SECURITIES PVT LTDbulkBuy424276195.8125 May 2026
ZAKI ABBAS NASSERbulkBuy400000189.4425 May 2026
NEO APEX SHARE BROKING SERVICES LLPbulkBuy500027188.6325 May 2026
SETU SECURITIES PVT LTDbulkSell424276193.9925 May 2026

Read More

Kopran Ltd News

Kopran Ltd FY26 Net Profit at ₹257.31 Cr

Kopran Ltd reported a consolidated net profit of ₹2,573.12 lakh for FY26. The Board recommended a dividend of ₹3.00 per share.

19 May 2026

companies

Kopran's Subsidiary Appoints Independent Director & Plans Rights Issue

Kopran Research Laboratories appoints Mr. Chandresh Gandhi as Additional Independent Director for 5 years and plans a rights issue at Rs.90/- premium to fund working capital.

18 May 2026

companies

Kopran Board Meeting Set for May 19, 2026

Kopran Ltd. has scheduled a Board of Directors meeting on May 19, 2026, to consider audited financial results for Q4 and FY26, along with a possible dividend recommendation.

06 May 2026

companies

Kopran Limited Announces Newspaper Publication for Merger

Kopran Limited published newspaper advertisements on May 2, 2026, in Free Press Journal and Navshakti regarding the merger with Kopran Laboratories Limited. NCLT-convened stakeholder meetings scheduled for June 3, 2026, with remote e-voting from May 27 to June 2.

04 May 2026

companies

Kopran Limited Schedules Merger Approval Meetings

Kopran Limited announces stakeholder meetings on June 3, 2026, to approve merger scheme with Kopran Laboratories Limited following NCLT order dated April 9, 2026.

01 May 2026

companies

Read More